Skip to main content
Erschienen in: Clinical Rheumatology 6/2018

10.10.2017 | Original Article

Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch–Schonlein purpura in children

verfasst von: Xu Teng, Cuiyun Gao, Mei Sun, Jie Wu

Erschienen in: Clinical Rheumatology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to explore the value of fecal calprotectin (FC) for early screening of the abdominal type of Henoch–Schonlein purpura (AHSP) in children. The study cohort included 40 children with AHSP treated at Shengjing Hospital of China Medical University from November 2014 to November 2015, and 40 children hospitalized in the Division of Pediatric Orthopedics in the corresponding period were selected as a control group. Fresh fecal samples were collected in the acute phase of the first visit (FC1), 3 days after treatment (FC2), and 7 days after treatment (FC3) from the AHSP group and the control group. Calprotectin levels in the fecal samples were measured using an enzyme-linked immunosorbent assay. At the same time, gastrointestinal performance and the laboratory examination indicators white blood cell (WBC) count and C-reactive protein (CRP) level were recorded. The median levels of FC1 (3053 μg/g) and FC2 (2778.3 μg/g) were higher than in the control group (102.5 μg/g), with significant differences among the three groups (p < 0.001). FC levels gradually decreased in remission, and the level of FC3 on day 7 was close to that of the control samples (p > 0.05). When the optimal cut-off was 264.5 μg/g, the area under the receiver operating characteristic (ROC) curve of FC for diagnosis of AHSP was 0.961 with a corresponding sensitivity and specificity of 93.1 and 87.5%, respectively. The levels of FC in children with AHSP were positively correlated with WBC count (r s = 0.688) and CRP value (r s = 0.513). The area under the ROC curve of WBC count for screening AHSP was 0.785 when the optimal cut-off value was 11.1 × 109/L with a corresponding sensitivity and specificity of 81.5 and 62.5%, respectively. The area under the ROC curve of CRP was 0.963 when the optimal cut-off value was 5.72 mg/dL with a corresponding sensitivity and specificity of 88.9 and 100%, respectively. Comparisons of FC, WBC count, and CRP level as diagnostic indicators of AHSP showed that the sensitivity of FC was higher than that of the WBC count and CRP level, and its diagnostic value was better than that of the WBC count. The levels of FC began to increase in the early stages of AHSP, showing a decreasing tendency in remission and tending to be within a normal range after a week or so. For the early diagnosis of AHSP, FC with a cut-off level of 264.5 μg/g has good sensitivity and specificity. The sensitivity of FC is better than that of the traditional inflammation indicators CRP and WBC count, and its diagnostic performance is better than WBC count; FC can be suitable as a new marker for the early diagnosis of AHSP.
Literatur
1.
Zurück zum Zitat Gardner-Medwin JM, Dolezalova P, Cummins C et al (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease and rare vasculitides in children of different ethnic origins. Lancet 360:1197–1202CrossRefPubMed Gardner-Medwin JM, Dolezalova P, Cummins C et al (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease and rare vasculitides in children of different ethnic origins. Lancet 360:1197–1202CrossRefPubMed
2.
Zurück zum Zitat Yamazaki T, Akimoto T, Iwazu Y et al (2015) Henoch-Schönlein purpura complicated with severe gastrointestinal bleeding. CEN Case Rep 4(1):106–111CrossRefPubMed Yamazaki T, Akimoto T, Iwazu Y et al (2015) Henoch-Schönlein purpura complicated with severe gastrointestinal bleeding. CEN Case Rep 4(1):106–111CrossRefPubMed
3.
Zurück zum Zitat Prathiba Rajalakshmi P, Srinivasan K (2015) Gastrointestinal manifestations of Henoch-Schonlein purpura: a report of two cases. World J Radiol 7(3):66–69CrossRefPubMedPubMedCentral Prathiba Rajalakshmi P, Srinivasan K (2015) Gastrointestinal manifestations of Henoch-Schonlein purpura: a report of two cases. World J Radiol 7(3):66–69CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Luo SH, Guo Q, Liu GJ (2016) Fasting for haemostasis in children with gastrointestinal bleeding. Cochrane Database Syst Rev 19(5):CD010714 Luo SH, Guo Q, Liu GJ (2016) Fasting for haemostasis in children with gastrointestinal bleeding. Cochrane Database Syst Rev 19(5):CD010714
5.
Zurück zum Zitat van Rheenen PF, de Vijver EV, Fidler V (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341:c3369CrossRefPubMedPubMedCentral van Rheenen PF, de Vijver EV, Fidler V (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341:c3369CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kwapisz L, Gregor J, Chande N et al (2017) The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scand J Gastroenterol 52(8):846–850CrossRefPubMed Kwapisz L, Gregor J, Chande N et al (2017) The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scand J Gastroenterol 52(8):846–850CrossRefPubMed
7.
Zurück zum Zitat Kotze LM, Nisihara RM, Marion SB et al (2015) FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol 52(1):50–54CrossRefPubMed Kotze LM, Nisihara RM, Marion SB et al (2015) FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol 52(1):50–54CrossRefPubMed
8.
Zurück zum Zitat Metafuni E, Giammarco S, De Ritis DG et al (2017) Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. Ann Hematol 96(6):929–933CrossRefPubMed Metafuni E, Giammarco S, De Ritis DG et al (2017) Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. Ann Hematol 96(6):929–933CrossRefPubMed
9.
Zurück zum Zitat Fagerberg UL, Loof L, Merzoug RD et al (2003) Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 37(4):468–472CrossRefPubMed Fagerberg UL, Loof L, Merzoug RD et al (2003) Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 37(4):468–472CrossRefPubMed
10.
Zurück zum Zitat The Subspecialty Group of immunology, Society of Pediatrics, Chinese Medical Association ,The Editorial Board of Chinese Journal of Pediatrics (2013) Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Henoch-Schonlein purpura. chin. J Pediatr 51(5):502–507 The Subspecialty Group of immunology, Society of Pediatrics, Chinese Medical Association ,The Editorial Board of Chinese Journal of Pediatrics (2013) Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Henoch-Schonlein purpura. chin. J Pediatr 51(5):502–507
11.
Zurück zum Zitat Micheletti RG, Werth VP (2015) Small vessel vasculitis of the skin. Rheum Dis Clin N Am 41(1):21–32CrossRef Micheletti RG, Werth VP (2015) Small vessel vasculitis of the skin. Rheum Dis Clin N Am 41(1):21–32CrossRef
12.
Zurück zum Zitat Woerner A, Rudin C, Bonetto C et al (2017) Brighton Collaboration lgA Vasculitis (Henoch–Schönlein) Working Group. IgA vasculitis (Henoch-Schönlein): case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 35(11):1559–1566CrossRefPubMed Woerner A, Rudin C, Bonetto C et al (2017) Brighton Collaboration lgA Vasculitis (Henoch–Schönlein) Working Group. IgA vasculitis (Henoch-Schönlein): case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 35(11):1559–1566CrossRefPubMed
13.
Zurück zum Zitat Hamzaoui A, Melki W, Harzallah O et al (2011) Gastrointestinal involvement revealing Henoch-Schonlein purpura in adults: report of three cases and review of the literature. Int Arch Med 4(1):31CrossRefPubMedPubMedCentral Hamzaoui A, Melki W, Harzallah O et al (2011) Gastrointestinal involvement revealing Henoch-Schonlein purpura in adults: report of three cases and review of the literature. Int Arch Med 4(1):31CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Grover N, Sankhyan N, Bisht JP et al (2007) A five year review of clinical profile in HSP. JNMA J Nepal Med Assoc 46(166):62–65PubMed Grover N, Sankhyan N, Bisht JP et al (2007) A five year review of clinical profile in HSP. JNMA J Nepal Med Assoc 46(166):62–65PubMed
15.
Zurück zum Zitat Fatima A, Gibson DP (2014) Pneumatosis intestinalis associated with Henoch-Schönlein purpura. Pediatrics 134(3):e880–e883CrossRefPubMed Fatima A, Gibson DP (2014) Pneumatosis intestinalis associated with Henoch-Schönlein purpura. Pediatrics 134(3):e880–e883CrossRefPubMed
16.
Zurück zum Zitat Zhang Y, Huang X (2008) Gastrointestinal involvement in Henoch-Schönlein purpura. Scand J Gastroenterol 43(9):1038–1043CrossRefPubMed Zhang Y, Huang X (2008) Gastrointestinal involvement in Henoch-Schönlein purpura. Scand J Gastroenterol 43(9):1038–1043CrossRefPubMed
17.
Zurück zum Zitat Foell D, Wittkowski H, Ren Z et al (2008) Phagocyte-specific S100 proteins are released from affected mucosa and promote immunoresponses during inflammatory bowel disease. J Pathol 216(2):183–192CrossRefPubMed Foell D, Wittkowski H, Ren Z et al (2008) Phagocyte-specific S100 proteins are released from affected mucosa and promote immunoresponses during inflammatory bowel disease. J Pathol 216(2):183–192CrossRefPubMed
18.
Zurück zum Zitat Campeotto F, Suau A, Kapel N et al (2011) A fermented formula in pre-term infants: clinical tolerance, gut microbiota, downregulation of faecal calprotectin and upregulation of faecal secretory IgA. Br J Nutr, 28;105(12):1843–1851 Campeotto F, Suau A, Kapel N et al (2011) A fermented formula in pre-term infants: clinical tolerance, gut microbiota, downregulation of faecal calprotectin and upregulation of faecal secretory IgA. Br J Nutr, 28;105(12):1843–1851
19.
Zurück zum Zitat Leach ST, Yang Z, Messina I et al (2007) Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11):1321–1331CrossRefPubMed Leach ST, Yang Z, Messina I et al (2007) Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11):1321–1331CrossRefPubMed
20.
Zurück zum Zitat Calafat M, Cabré E, Mañosa M et al (2015) High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what ss the best timing for stool sampling? Inflamm Bowel Dis 21(5):1072–1076CrossRefPubMed Calafat M, Cabré E, Mañosa M et al (2015) High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what ss the best timing for stool sampling? Inflamm Bowel Dis 21(5):1072–1076CrossRefPubMed
21.
Zurück zum Zitat Hradsky O, Ohem J, Mitrova K et al (2014) Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings. Clin Lab 60(12):1993–2000PubMed Hradsky O, Ohem J, Mitrova K et al (2014) Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings. Clin Lab 60(12):1993–2000PubMed
22.
23.
Zurück zum Zitat Moniuszko A, Głuszek S, Rydzewska G (2017) Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study. Pol Arch Intern Med 127(5):312–318PubMed Moniuszko A, Głuszek S, Rydzewska G (2017) Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study. Pol Arch Intern Med 127(5):312–318PubMed
24.
Zurück zum Zitat Marie I, Leroi AM, Menard JF et al (2015) Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 14(6):547–554CrossRefPubMed Marie I, Leroi AM, Menard JF et al (2015) Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 14(6):547–554CrossRefPubMed
25.
Zurück zum Zitat Zittan E, Kelly OB, Kirsch R et al (2016) Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s Disease. Inflamm Bowel Dis 22(3):623–630CrossRefPubMed Zittan E, Kelly OB, Kirsch R et al (2016) Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s Disease. Inflamm Bowel Dis 22(3):623–630CrossRefPubMed
26.
Zurück zum Zitat Bjarnason I (2017) The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 13(1):53–56 Bjarnason I (2017) The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 13(1):53–56
27.
Zurück zum Zitat Heida A, Park KT, van Rheenen PF (2017) Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 23(6):894–902CrossRefPubMed Heida A, Park KT, van Rheenen PF (2017) Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 23(6):894–902CrossRefPubMed
28.
Zurück zum Zitat Aydemir G, Cekmez F, Tanju IA et al (2012) Increased fecal calprotectin in preterm infants with necrotizing enterocolitis. Clin Lab 58(7–8):841–844PubMed Aydemir G, Cekmez F, Tanju IA et al (2012) Increased fecal calprotectin in preterm infants with necrotizing enterocolitis. Clin Lab 58(7–8):841–844PubMed
29.
Zurück zum Zitat Al K, Baran M, Ince FD et al (2015) Faecal calprotectin levels in children with Henoch-Schönlein purpura: is this a new marker for gastrointestinal involvement? Eur J Gastroenterol Hepatol 27(3):254–258 Al K, Baran M, Ince FD et al (2015) Faecal calprotectin levels in children with Henoch-Schönlein purpura: is this a new marker for gastrointestinal involvement? Eur J Gastroenterol Hepatol 27(3):254–258
30.
Zurück zum Zitat Burri E, Beglinger C (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 8(2):197–210CrossRefPubMed Burri E, Beglinger C (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 8(2):197–210CrossRefPubMed
31.
Zurück zum Zitat Flagstad G, Helgeland H, Markestad T (2010) Faecal calprotectin concentrations in children with functional gastrointestinal disorders diagnosed according to the Pediatric Rome III criteria. Acta Paediatr 99(5):734–737CrossRefPubMed Flagstad G, Helgeland H, Markestad T (2010) Faecal calprotectin concentrations in children with functional gastrointestinal disorders diagnosed according to the Pediatric Rome III criteria. Acta Paediatr 99(5):734–737CrossRefPubMed
32.
Zurück zum Zitat Shulman RJ, Eakin MN, Czyzewski DI et al (2008) Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 153(5):646–650CrossRefPubMedPubMedCentral Shulman RJ, Eakin MN, Czyzewski DI et al (2008) Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 153(5):646–650CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Berni Canani R, Rapacciuolo L, Romano MT et al (2004) Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 36(7):467–470CrossRefPubMed Berni Canani R, Rapacciuolo L, Romano MT et al (2004) Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 36(7):467–470CrossRefPubMed
Metadaten
Titel
Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch–Schonlein purpura in children
verfasst von
Xu Teng
Cuiyun Gao
Mei Sun
Jie Wu
Publikationsdatum
10.10.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 6/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3864-6

Weitere Artikel der Ausgabe 6/2018

Clinical Rheumatology 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.